Month: August 2024

All amounts are stated in United States dollars unless otherwise indicatedRevenue of $11.4 million Total Contract Value (“TCV”)(1) bookings of $13.2 million Gross margin of 56% Adjusted EBITDA(1) loss of $1.7 million EPS loss of $ 0.90 $17.1 million of cashTORONTO, Aug. 08, 2024 (GLOBE NEWSWIRE) — Optiva Inc. (“Optiva” or “the Company”) (TSX:OPT), a leader in powering the telecom industry with cloud-native billing, charging and revenue management software on private and public clouds, today released its second quarter financial results for the three-month period ended June 30, 2024. In the second quarter, Optiva secured a full BSS upgrade for a key customer, one of the largest Tier 1 mobile operators in Mexico, that will be deployed on Google Cloud. The company also extended other strategic Tier 1 customers with multi-year...

TORONTO, Aug. 08, 2024 (GLOBE NEWSWIRE) — SmartCentres Real Estate Investment Trust (“SmartCentres” or the “Trust”) (TSX: SRU.UN) is pleased to report its financial and operating results for the quarter ended June 30, 2024. “Building on Q1, we are pleased to report strong continued momentum in leasing demand and lease deals executed for space in Q2”, said Mitchell Goldhar, CEO of SmartCentres. “Occupancy has improved by 50 basis points to 98.2% with approximately 272,000 square feet of vacant space leased during the quarter and rent growth of 8.5% (excluding anchors). The Millway, our purpose-built rental project in the VMC continues to experience strong leasing momentum with occupancy at 88% by the end of the quarter, 90% currently, and expected to exceed 95% by year-end, all at average rental rates above our original budget....

FDA provided clearance to SAB’s IND Appointed Lucy To as Chief Financial Officer Announced founding of a new Clinical Advisory Board MIAMI, Aug. 08, 2024 (GLOBE NEWSWIRE) — SAB BIO (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today reported financial results for the second quarter ended June 30, 2024, and provided a company update. “We’ve had a strong quarter as we drive closer to our upcoming SAB-142 milestones. We continue to see an urgent need for transformative therapies in this space, and specifically for innovative approaches like SAB-142 which could delay or stop the progression of type 1 diabetes,” notes SAB chairman and...

Increased Ability’s total assets managed by Mount Logan to $636 million and reinsured an additional $28 million Multi-Year Guaranteed Annuities (“MYGA”) during the quarter Generated $11.6 million of insurance segment Spread Related Earnings (“SRE”) for the trailing twelve months ended June 30, 2024, an increase of 314% over the prior year period, demonstrating the earnings power of the insurance segment Record quarter for the asset management segment, earning $3.8 million in management and incentive fees, an increase of 79% over the prior year period. Achieved Fee Related Earnings (“FRE”) of $1.6 million, up 6% as compared to second quarter 2023 During the quarter, Mount Logan and BC Partners announced the Opportunistic Credit Interval Fund (“SOFIX”) passed $100 million AUM. Fund raising accelerated following the milestone achievement...